InsiderTrades

Form 4 for AGIO AGIOS PHARMACEUTICALS, INC.

Accepted 2024-01-24 00:00:00 ET · period of report 2024-01-20 · accession 0001439222-24-000014 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-01-24 2024-01-20 AGIO Goff Brian CEO, Dir M - OptEx $0.00 +17.0K 57.1K +42% $0
D 2024-01-24 2024-01-24 AGIO Goff Brian CEO, Dir S - Sale+OE $21.64 -7,635 49.4K -13% -$165.2K
D 2024-01-24 2024-01-20 AGIO Goff Brian CEO, Dir M - OptEx $0.00 -17.0K 102.1K -14% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common stock 2024-01-20 M A 17,018 $0.00 57,071 D — —
2 Common Common stock 2024-01-24 S D 7,635 $21.64 49,436 D — —
3 Derivative Performance share units 2024-01-20 M D 17,018 $0.00 102,110 D — · — to — 17,018 Common stock (F2) Each performance share unit represents a contingent right to receive one share of the issuer's common stock. (F3) The PSUs were granted on August 8, 2022. The PSUs vest as to 10% of the underlying shares upon the achievement of a specified research milestone and as to the remaining underlying shares upon the achievement of other clinical, research and regulatory milestones. The performance criteria for the specified research milestone was determined to have been met on January 20, 2024, resulting in the vesting of the PSUs as to 10% of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested.